The Discovery of Novel β-Secretase Inhibitors: Pharmacophore Modeling, Virtual Screening, and Docking Studies

Chemical Biology and Drug Design

Volumn 79, Issue 6, 2012, Pages 972-980

  Niu, Yan ^a   Ma, Chao ^a   Jin, Hongwei ^a   Xu, Fengrong ^a   Gao, Haifei ^a   Liu, Peng ^a   Li, Yongjian ^a   Wang, Chao ^a   Yang, Guanyu ^a   Xu, Ping ^a  

^a PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

Author keywords

secretase inhibitor; Molecular docking; Pharmacophore modeling; Virtual screening

Indexed keywords

B 47; B 48; B 49; B 50; B 51; B 52; B 53; B 54; B 55; B 56; BETA SECRETASE INHIBITOR; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; ARTICLE; DRUG INDICATION; DRUG ISOLATION; DRUG SCREENING; DRUG STRUCTURE; DRUG SYNTHESIS; FLUORESCENCE RESONANCE ENERGY TRANSFER; IC 50; MOLECULAR DOCKING; PHARMACOPHORE; PRIORITY JOURNAL; STRUCTURE ACTIVITY RELATION; VALIDATION STUDY;

AMYLOID PRECURSOR PROTEIN SECRETASES; BINDING SITES; COMPUTER SIMULATION; DATABASES, FACTUAL; DRUG EVALUATION, PRECLINICAL; LIGANDS; PROTEASE INHIBITORS; PROTEIN STRUCTURE, TERTIARY;

EID: 84860457503     PISSN: 17470277     EISSN: 17470285     Source Type: Journal    
DOI: 10.1111/j.1747-0285.2012.01367.x     Document Type: Article

References (46)

1. Cummings J.L. (2004) Alzheimer's disease. N Engl J Med;351:56-67.
2. Hardy J. (1997) The Alzheimer family of diseases: many etiologies, one pathogenesis? Proc Natl Acad Sci USA;94:2095-2097.
3. Celsis P. (2000) Age-related cognitive decline, mild cognitive impairment or pre-clinical Alzheimer's disease. Ann Med;32:6-14.
4. Stavrovskaya I.G., Kristal B.S. (2005) The powerhouse takes control of the cell: is the mitochondrial permeability transition a viable therapeutic target against neuronal dysfunction and death? Free Radical Biol Med;38:687-697.
5. Selkoe D.J. (1997) Alzheimer disease: genotypes, phenotypes, and treatments. Science;275:630-631.
6. Nguyen J., Yamani A., Kiso Y. (2006) Views on amyloid hypothesis and secretase inhibitors for treating Alzheimer's disease: progress and problems. Curr Pharm Des;12:4295-4312.
7. Iwatsubo T., Odaka A., Suzuki N., Mizusawa H., Nukina N., Ihara Y. (1994) Visualization of Aβ42(43) and Aβ40 in senile plaques with end-specific Aβ monoclonals: evidence that an initially deposited species is Aβ42(43). Neuron;13:45-53.
8. Milligan C. (2000) Caspase cleavage of APP results in a cytotoxic proteolytic peptide. Nat Med;6:385-386.
9. St George-Hyslop P.H., Morris J.C. (2008) Will anti-amyloid therapies work for Alzheimer's disease? Lancet;372:180-182.
10. Ghosh A.K., Bilcer G., Hong L., Koelsch G., Tang J. (2007) Memapsin 2 (beta-secretase) inhibitor drug, between fantasy and reality. Curr Alzheimer Res;4:418-422.
11. Durham T.B., Shepherd T.A. (2006) Progress toward the discovery and development of efficacious BACE inhibitors. Curr Opin Drug Discov Devel;9:776-791.
12. Wolfe M.S. (2001) Secretase targets for Alzheimer's disease: identification and therapeutic potential. J Med Chem;44:2039-2060.
13. John V., Beck J.P., Bienkowski M.J., Sinha S., Heinrikson R.L. (2003) Human beta-secretase (BACE) and BACE inhibitors. J Med Chem;46:4625-4630.
14. Citron M. (2010) Alzheimer's disease: strategies for disease modification. Nat Rev Drug Discov;9:387-398.
15. Cumming J.N., Iserloh U., Kennedy M.E. (2004) Design and development of BACE-1 inhibitors. Curr Opin Drug Discov Devel;7:536-556.
16. Silvestri R.I.P., Fondazione C.B. (2009) Boom in the development of non-peptidic beta-secretase (BACE1) inhibitors for the treatment of Alzheimer's disease. Med Res Rev;29:295-338.
17. Beck J.P., Mergott D.J. (2010) Peptidic, peptidomimetic and HTS-derived BACE inhibitors. In: BACE: Lead target for Orchestrated Therapy of Alzheimer's Disease, Varghese, J. Ed., New Jersey: John Wiley & Sons, Inc., Hoboken, New Jersey; p. 59-105.
18. Huang D., Luthi U., Kolb P., Cecchini M., Barberis A., Caflisch A. (2006) In silico discovery of beta-secretase inhibitors. J Am Chem Soc;128:5436-5443.
19. Fujimoto T., Matsushita Y., Gouda H., Yamaotsu N., Hirono S. (2008) In silico multi-filter screening approaches for developing novel beta-secretase inhibitors. Bioorg Med Chem Lett;18:2771-2775.
20. Chiriano G., Sartini A., Mancini F., Andrisano V., Bolognesi M.L., Roberti M., Recanatini M., Carloni P., Cavalli A. (2011) Sequential virtual screening approach to the identification of small organic molecules as potential BACE-1 inhibitors. Chem Biol Drug Des;77:268-271.
21. Weijun X., Gang C., Oi W.L., Zhili Z., Hualiang J., Weiliang Z. (2009) Novel non-peptide β-secretase inhibitors derived from structure-based virtual screening and bioassay. Bioorg Med Chem Lett;19:3188-3192.
22. Xu W., Chen G., Zhu W., Zuo Z. (2010) Identification of a sub-micromolar, non-peptide inhibitor of β-secretase with low neural cytotoxicity through in silico screening. Bioorg Med Chem Lett;20:5763-5766.
23. Vijayan R.S.K., Prabu M., Mascarenhas N.M., Ghoshal N. (2009) Hybrid structure-based virtual screening protocol for the identification of novel BACE1 inhibitors. J Chem Inf Model;49:647-657.
24. John S., Thangapandian S., Sakkiah S., Lee K.W. (2011) Potent BACE-1 inhibitor design using pharmacophore modeling, in silico screening and molecular docking studies. BMC Bioinformatics;12(Suppl 1):S28.
25. Al-Nadaf A., Abu Sheikha G., Taha M.O. (2010) Elaborate ligand-based pharmacophore exploration and QSAR analysis guide the synthesis of novel pyridinium-based potent β-secretase inhibitory leads. Bioorg Med Chem;18:3088-3115.
26. Huang W., Yu H., Sheng R., Li J., Hu Y. (2008) Identification of pharmacophore model, synthesis and biological evaluation of N-phenyl-1-arylamide and N-phenylbenzenesulfonamide derivatives as BACE 1 inhibitors. Bioorg Med Chem;16:10190-10197.
27. Irwin J.J., Shoichet B.K. (2005) ZINC-A free database of commercially available compounds for virtual screening. J Chem Inf Model;45:177-182.
28. Robert T.T., Lin H., Gerald K., Arun K.G., Jordan T. (2005) Structural locations and functional roles of new subsites S5, S6, and S7 in memapsin 2 (β-Secretase). Biochemistry;44:105-112.
29. Lin H., Gerald K., Xinli L., Shili W., Simon T., Arun K.G., Xuenjun C.Z., Jordan T. (2000) Structure of the protease domain of memapsin 2 (β-secretase) complexed with inhibitor. Science;290:150-153.
30. Lin H., Robert T.T. III, Gerald K., Dongoo S., Arun K.G., Jordan T. (2002) Crystal structure of memapsin 2 (β-secretase) in complex with an inhibitor OM00-3. Biochemistry;41:10963-10967.
31. Ghosh A.K., Devasamudram T., Hong L., DeZutter C., Xu X., Weerasena V., Koelsch G., Bilcer G., Tang J. (2005) Structure-based design of cycloamide-urethane-derived novel inhibitors of human brain memapsin 2 (beta-secretase). Bioorg Med Chem Lett;15:15-20.
32. Hanessian S., Yun H., Hou Y., Yang G., Bayrakdarian M., Therrien E., Moitessier N. et al. (2005) Structure-based design, synthesis, and memapsin 2 (BACE) inhibitory activity of carbocyclic and heterocyclic peptidomimetics. J Med Chem;48:5175-5190.
33. Ghosh A.K., Kumaragurubaran N., Hong L., Lei H., Hussain K.A., Liu C.F., Devasamudram T., Weerasena V., Turner R., Koelsch G., Bilcer G., Tang J. (2006) Design, synthesis and X-ray structure of protein-ligand complexes: important insight into selectivity of memapsin 2 (beta-secretase) inhibitors. J Am Chem Soc;128:5310-5311.
34. Coburn C.A., Stachel S.J., Li Y.M., Rush D.M., Steele T.G., Chen-Dodson E., Holloway M.K. et al. (2004) Identification of a small molecule nonpeptide active site beta-secretase inhibitor that displays a nontraditional binding mode for aspartyl proteases. J Med Chem;47:6117-6119.
35. Patel S., Vuillard L., Cleasby A., Murray C.W., Yon J. (2004) Apo and inhibitor complex structures of BACE (beta-secretase). J Mol Biol;343:407-416.
36. Stachel S.J., Coburn C.A., Steele T.G., Jones K.G., Loutzenhiser E.F., Alison R.G., Hemaka A.R. et al. (2004) Structure-based design of potent and selective cell-permeable inhibitors of human β-secretase (BACE-1). J Med Chem;47:6447-6450.
37. Shawn J.S., Craig A.C., Thomas G.S., Min-Chi C., Beth L.P., Ming-Tain L., Holloway M.K., Sanjeev K.M., Samuel L.G., Joseph P.V. (2006) Conformationally biased P3 amide replacements of β-secretase inhibitors. Bioorg Med Chem Lett;16:641-644.
38. Wenjin Y., Wanli L., Yafan L., Min Z., Jian S., Anila E.T., Jennifer M.W., Raymond V.F., Melissa L., Mike R., Xiao-Ping S., Jeffrey W.J., Robert S.M., Eric M.G., Marcus D.B. (2006) Aminoethylenes: a tetrahedral intermediate isostere yielding potent inhibitors of the aspartyl protease BACE-1. J Med Chem;49:839-842.
39. Berman H.M., Westbrook J., Feng Z., Gilliland G., Bhat T.N., Weissig H., Shindyalov I.N., Bourne P.E. (2000) The protein data bank. Nucleic Acids Res;28:235-242.
40. Lipinski C.A. (2000) Drug-like properties and the causes of poor solubility and poor permeability. J Pharmacol Toxicol Methods;44:235-249.
41. Huang N., Shoichet B.K., Irwin J.J. (2006) Benchmarking sets for molecular docking. J Med Chem;49:6789-6801.
42. Schuster D., Wolber G. (2010) Identification of bioactive natural products by pharmacophore-based virtual screening. Curr Pharm Des;16:1666-1681.
43. McGaughey G.B., Holloway M.K. (2007) Structure-guided design of β-secretase (BACE-1) inhibitors. Expert Opin Drug Discov;2:1-10.
44. Jones G., Willent P., Glen R.C., Lench A.R., Taylor R. (1997) Development and validation of a genetic algorithm for flexible docking. J Mol Biol;267:727-748.
45. Wu J.J., Hockenbery D.M., Wang L., Guo J. Compositions and methods using triazines and other heterocyclic compounds for modulating apoptosis in cells over-expressing Bcl-2 family member proteins. WO 2008021250A2.
46. Veber D.F., Johnson S.R., Cheng H.Y., Smith B.R., Ward K.W., Kopple K.D. (2002) Molecular properties that influence the oral bioavailability of drug candidates. J Med Chem;45:2615-2623.